Shah Vandit, Shah Jigna
Institute of Pharmacy, Nirma University, Ahmedabad, India.
Front Cardiovasc Med. 2022 Feb 10;9:835138. doi: 10.3389/fcvm.2022.835138. eCollection 2022.
Human heart development is a complex and tightly regulated process, conserving proliferation, and multipotency of embryonic cardiovascular progenitors. At terminal stage, progenitor cell type gets suppressed for terminal differentiation and maturation. In the human heart, most cardiomyocytes are terminally differentiated and so have limited proliferation capacity. MicroRNAs (miRNAs) are non-coding single-stranded RNA that regulate gene expression and mRNA silencing at the post-transcriptional level. These miRNAs play a crucial role in numerous biological events, including cardiac development, and cardiomyocyte proliferation. Several cardiac cells specific miRNAs have been discovered. Inhibition or overexpression of these miRNAs could induce cardiac regeneration, cardiac stem cell proliferation and cardiomyocyte proliferation. Clinical application of miRNAs extends to heart failure, wherein the cell cycle arrest of terminally differentiated cardiac cells inhibits the heart regeneration. The regenerative capacity of the myocardium can be enhanced by cardiomyocyte specific miRNAs controlling the cell cycle. In this review, we focus on cardiac-specific miRNAs involved in cardiac regeneration and cardiomyocyte proliferation, and their potential as a new clinical therapy for heart regeneration.
人类心脏发育是一个复杂且受到严格调控的过程,它维持着胚胎心血管祖细胞的增殖和多能性。在终末阶段,祖细胞类型会受到抑制以进行终末分化和成熟。在人类心脏中,大多数心肌细胞是终末分化的,因此增殖能力有限。微小RNA(miRNA)是一类非编码单链RNA,可在转录后水平调控基因表达和mRNA沉默。这些miRNA在包括心脏发育和心肌细胞增殖在内的众多生物学事件中发挥着关键作用。已经发现了几种心脏细胞特异性miRNA。抑制或过表达这些miRNA可诱导心脏再生、心脏干细胞增殖和心肌细胞增殖。miRNA的临床应用扩展到心力衰竭领域,在心力衰竭中,终末分化心脏细胞的细胞周期停滞会抑制心脏再生。通过控制细胞周期的心肌细胞特异性miRNA可以增强心肌的再生能力。在本综述中,我们重点关注参与心脏再生和心肌细胞增殖的心脏特异性miRNA,以及它们作为心脏再生新临床疗法的潜力。